HIV-1-infection Clinical Trial
Official title:
SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian Youth
The overall objectives of this proposal are to support positive coping strategies that bolster mental health and lead to improved HIV outcomes among Young People Living with HIV (YPLWH). The central hypothesis is that SYV (Sauti ya Vijana, The Voice of Youth) will be effective to improve antiretroviral therapy (ART) adherence and virologic suppression in YPLWH in Tanzania. The rationale for this project is that by targeting mental health, which is strongly associated with medication adherence, that this will effectively improve adherence and thereby HIV viral suppression. The central hypothesis will be tested in three aims in a hybrid type-1 effectiveness-implementation trial.
Status | Recruiting |
Enrollment | 750 |
Est. completion date | January 31, 2026 |
Est. primary completion date | February 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 24 Years |
Eligibility | Inclusion Criteria: - Youth between the ages of 10 and 24 years of age - Attending the enrolling adolescent HIV clinic - Are fully disclosed and aware of their HIV status - Receiving ART for a minimum of 6 months - If = 18 years, able to understand the project and provide written informed consent - If <18 years, a parent or guardian must provide written permission and participant must be able to assent - All adolescents must also commit to attending the 10 weekly SYV sessions and 2 individual sessions Exclusion Criteria: - Active psychosis - Developmental delay, or cognitive disability that precludes active participation in consent process, intervention, and assessment interviews |
Country | Name | City | State |
---|---|---|---|
Tanzania | Chronic Disease Clinic of Ifakara Health Institute | Ifakara | |
Tanzania | Baylor College of Medicine Children's Foundation - Tanzania, Mbeya Centre for Excellence | Mbeya | |
Tanzania | Kilimanjaro Christian Medical Centre | Moshi | |
Tanzania | Mawenzi Regional Referral Hospital | Moshi | |
Tanzania | Baylor College of Medicine Children's Foundation - Tanzania, Mwanza Centre for Excellence | Mwanza | |
Tanzania | Bugando Medical Centre | Mwanza |
Lead Sponsor | Collaborator |
---|---|
Duke University | Kilimanjaro Christian Medical Centre, Tanzania, National Institute for Medical Research, Tanzania, National Institute of Mental Health (NIMH) |
Tanzania,
Dow DE, Mmbaga BT, Gallis JA, Turner EL, Gandhi M, Cunningham CK, O'Donnell KE. A group-based mental health intervention for young people living with HIV in Tanzania: results of a pilot individually randomized group treatment trial. BMC Public Health. 2020 Sep 4;20(1):1358. doi: 10.1186/s12889-020-09380-3. — View Citation
Dow DE, Mmbaga BT, Turner EL, Gallis JA, Tabb ZJ, Cunningham CK, O'Donnell KE. Building resilience: a mental health intervention for Tanzanian youth living with HIV. AIDS Care. 2018;30(sup4):12-20. doi: 10.1080/09540121.2018.1527008. Epub 2019 Jan 9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Virologic suppression as measured by percent of patients with a HIV RNA <400 copies/mL | HIV RNA measured by blood testing | 6 months post-baseline visit | |
Secondary | Change in virologic suppression as measured by percent of patients with a HIV RNA <400 copies/mL | HIV RNA measured by blood testing | Baseline, months 4, 12 and 18 post-baseline visit | |
Secondary | Change in the percentage of patients who are HIV RNA undetectable (<400 copies m/L) as measured by blood test | HIV RNA results | Baseline, months 4, 6, 12 and 18 post-baseline visit | |
Secondary | Change in the percentage of patients who are HIV RNA detectable (>400 copies m/L) as measured by blood test | HIV RNA results | Baseline, months 4, 6, 12 and 18 post-baseline visit | |
Secondary | Change in anti-retroviral therapy (ART) adherence as measured by SYV (Sauti ya Vijana) Scale - Adherence section | SYV Scale - Adherence section (Likert scale - not applicable) | Baseline, months 4, 6, 12 and 18 post-baseline visit | |
Secondary | Change in anti-retroviral therapy (ART) adherence as measured by concentration of ART medication(s) in hair sample | hair samples sent for analysis | Baseline, months 4, 6, 12 and 18 post-baseline visit | |
Secondary | Change in mental health status as measured by SYV Scale - General Anxiety Disorder-7 (GAD-7) section | SYV Scale - General Anxiety Disorder-7 (GAD-7) section (Likert scale 0 not at all to 3 nearly every day) 0 is the most positive choice | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in mental health status as measured by SYV Scale - Patient Health Questionnaire-9 (PHQ-9) section | SYV Scale - Patient Health Questionnaire-9 (PHQ-9) section (Likert scale 0 not at all to 3 nearly every day) 0 is the most positive choice | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in mental health status as measured by SYV Scale - Strengths and Difficulties Questionnaire (SDQ) section | SYV Scale - Strengths and Difficulties Questionnaire (SDQ) section (Likert scale 0 never true of me to 2 usually true of me) 0 or 2 can be most positive or most negative choices depending on the question | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in mental health status as measured by SYV Scale - Self-Esteem section | SYV Scale - Self-Esteem section (Likert scale - 4 options from strongly agree to strongly disagree - no choice is most positive) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in mental health status as measured by SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section | SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section (Likert scale - 5 options from Always to Never - Always is the most positive choice, 5 options Many Times, A few times, Once, Never or Refused - Never is the most positive choice, 4 options None, Little, Much and Most - no choice is the most positive and 3 options are Yes, No or Not Sure - No is the most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in coping habits as measured by SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section | SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section (Likert scale - 5 options from Always to Never - Never is the most positive choice, 5 options Many Times, A few times, Once, Never or Refused - Never is the most positive choice, 4 options None, Little, Much and Most - no choice is most positive and 3 options are Yes, No or Not Sure - No is the most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in resilience as measured by SYV Scale - Adapted People Living with HIV Resilience Scale | SYV Scale - Adapted People Living with HIV Resilience Scale (Likert scale 5 options from strongly disagree to strongly agree - strongly agree is the most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in stigma as measured by SYV Scale - Stigma section | SYV Scale - Stigma section (Likert scale 1 strongly disagree to 4 strongly agree - no most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in overall quality of life measured by SYV Scale - Quality of Life (QOL) | SYV Scale - Quality of Life (QOL) (Likert scale 5 options from very poor/very dissatisfied to very good/very satisfied - very good/very satisfied is the most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in gender based violence as measured by SYV Scale - Violence against partner section | SYV Scale - Violence against partner section (Likert scale Yes or No - No is the most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in gender based violence as measured by SYV Scale - Violence Perpetration section | SYV Scale - Violence Perpetration section (Likert scale Yes or No - No is the most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in disclosure as measured by SYV Scale - Stigma section | SYV Scale - Stigma section (Likert scale 1 strongly disagree to 4 strongly agree - strongly disagree is the most positive choice) and Sexual section (Likert scale - N/A) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in HIV knowledge as measured by SYV Scale - HIV Knowledge Questionnaire-18 (HIV-KQ-18) section | SYV Scale - HIV Knowledge Questionnaire-18 (HIV-KQ-18) section (Likert scale True/False/I don't know - no most positive choice) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in sexual high-risk behaviors as measured by SYV Scale - Sexual section | SYV Scale - Sexual section (Likert scale - N/A) | Baseline, 4, 6, 12 and 18 months post-baseline visit | |
Secondary | Change in substance abuse high-risk behaviors as measured by SYV Scale - Personal section | SYV Scale - Personal section (Likert scale N/A) | Baseline, 4, 6, 12 and 18 months post-baseline visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03940521 -
Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
|
||
Completed |
NCT03227731 -
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women
|
Phase 2/Phase 3 | |
Completed |
NCT03570918 -
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04022967 -
ANRS 12372 MODERATO Study
|
Phase 3 | |
Not yet recruiting |
NCT06282783 -
Studying Topiramate for Re-Activating the HIV-1 Reservoir
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06337032 -
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
|
Phase 4 | |
Completed |
NCT04711265 -
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
|
||
Recruiting |
NCT03536234 -
Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients
|
Phase 2 | |
Completed |
NCT04340388 -
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
|
Phase 4 | |
Withdrawn |
NCT05769569 -
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
|
Phase 1 | |
Enrolling by invitation |
NCT05584397 -
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
|
||
Completed |
NCT04388904 -
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
|
Phase 4 | |
Not yet recruiting |
NCT04894357 -
Impact of V106I on Resistance to Doravirine
|
||
Completed |
NCT04963712 -
Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
|
Early Phase 1 | |
Not yet recruiting |
NCT04311944 -
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
|
N/A | |
Completed |
NCT04568239 -
Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
|
||
Not yet recruiting |
NCT04513496 -
Telemedicine in HIV Care in Buenos Aires
|
||
Not yet recruiting |
NCT04311957 -
Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults
|
Phase 4 | |
Completed |
NCT03998176 -
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
|
Phase 4 |